Coherus Oncology (CHRS) Capital Expenditures (QoQ) (2014 - 2025)
Coherus Oncology (CHRS) Capital Expenditures (QoQ) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -10,343.70% |
| Jun 30, 2024 | 78.70% |
| Mar 31, 2024 | -552,520.59% |
| Jun 30, 2023 | -34.21% |
| Mar 31, 2023 | 74.71% |
| Dec 31, 2022 | -80.96% |
| Sep 30, 2022 | -48.07% |
| Jun 30, 2022 | 43.09% |
| Mar 31, 2022 | 31.41% |
| Dec 31, 2021 | 79.31% |
| Sep 30, 2021 | -37.11% |
| Jun 30, 2021 | 186.21% |
| Mar 31, 2021 | -84.77% |
| Dec 31, 2020 | -54.92% |
| Sep 30, 2020 | -11.41% |
| Jun 30, 2020 | 33.71% |
| Mar 31, 2020 | 34.87% |
| Dec 31, 2019 | 7,876.47% |
| Sep 30, 2019 | -109.34% |
| Jun 30, 2019 | -45.67% |